PDCD1 and metastatic melanoma: In a study of patients with metastatic melanoma who progressed on first line anti-PD-1 therapy treated with ipilimumab and an anti-PD-1, five out of 15 (33%) patients developed grade 3–4 irAEs leading to treatment discontinuation (Mehmi and Hill 2018).